Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Completed NCT07226778

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

Conditions: Overweight, Obesity

Sex: All

Ages: 18 Years – 60 Years

Healthy volunteers: No

Phase: PHASE1

Enrollment: 348

Sponsor: Amgen

Location: Anaheim Clinical Trials Anaheim California

Summary

The main objective of this trial is to evaluate the pharmacokinetics (PK) of maridebart cafraglutide administered as a single dose using two different SC presentations in participants living with overweight or obesity.

Eligibility Criteria

Inclusion Criteria 1. Male or female, of any race, between 18 and 60 years of age, inclusive. a. Females must not be pregnant or lactating. 2. Body mass index between ≥25.0 and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07226778). StuddyBuddy aggregates publicly available trial information.